- Company has completed steps necessary to achieve, sustain competitive advantage in move towards remote-health solutions and trials
- RYAH technology optimizes patient feedback so medical trials, studies can move into remote solution zones
- Recently developed an integrated, customized mobile application to support a major clinical study in the United Kingdom
- RYAH created cloud of stored data to help with R&D of future medical treatments
RYAH Group, a leading digital health-care analytics and technology company, is on a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. The company believes that, when patients are given more control overdosing, doctors can offer personalized treatment plans based on collective information.
Accenture, a global professional service company, recently surveyed 128 life science industry leaders to better understand digital transformation in the lab. The survey results revealed the following three key steps, which life science companies must take in order to achieve and sustain a competitive advantage in a world with enormous amounts of data to sift through (https://cnw.fm/Y2Ahd):
- Lay the groundwork with automation, connecting all instruments and digital data capturing
- Move toward a cloud-based, multivendor platform with enhanced security, data access, instrument integration and more with analytics powered insights to enhance workflow and compliance
- Create and power an end-to-end data supply chain, deeper adoption of AI, with whole lab automation and implementation
RYAH is meeting each of these steps head-on by creating useful technology that collects, analyzes and leverages objective data on therapeutic plant usage. Patients can set usage limits, track usage in real time, record how they feel after sessions and review stats over time. The patient controls the process, and the instruments that collect digital data remain anonymous.
When patient feedback is optimized, medical trials and studies can move into remote solution zones. RYAH has recently developed a custom solution where a patient session temperature and dosing is set and locked by the clinical partner, suitable for both medium- and large-scale studies.
In 2013 the FDA suggested a shift to remote monitoring (https://cnw.fm/ZrUnU), but the industry has been slow to adopt the necessary technology — until COVID-19 made it nearly impossible to conduct traditional monitoring. In today’s pandemic setting, more clinical trials are needed that connect patients and researchers without the need for in-person monitoring or unnecessary risk to exposure.
Communication between the monitor and the patient is essential. Notifications, in-app messaging and push notifications help create personalized plans for patients, tailored to their unique conditions and tolerance of the treatment.
RYAH is focused on expanding the understanding of proprietary technology that supports a data-driven approach to positively impact patients’ future treatment for various medical conditions. By coupling a anonymous database with AI, the company has created a cloud of stored data to help with the R&D of future medical treatments. RYAH is actively making digital transformation in the lab a reality, paving the way forward for a medical future with remote solutions.
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://cnw.fm/RYAH
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.